A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction

J Am Coll Cardiol. 1996 May;27(6):1321-6. doi: 10.1016/0735-1097(96)00008-3.


Objectives: This study was done to determine the incidence, timing and prevalence as a cause of death from cardiac rupture in patients with acute myocardial infarction.

Background: Several clinical trials and overview analyses have suggested that the survival benefit conferred by thrombolytic therapy may be offset by a paradoxic increase in early deaths from cardiac rupture.

Methods: Demographic, procedural and outcome data from patients with acute myocardial infarction were collected at 1,073 United States hospitals collaborating in the United States National Registry of Myocardial Infarction.

Results: Among the 350,755 patients enrolled, 122,243 received thrombolytic therapy. In-hospital mortality for the overall patient population, those not treated with thrombolytics (n = 228,512) and those given thrombolytics were 10.4%, 12.9% and 5.9%, respectively (p<0.001). Cardiogenic shock was the most common cause of death in each patient group. Although the incidence of cardiac rupture was low (<1.0%), it was responsible for 7.3%, 6.1% and 12.1%, respectively, of in-hospital deaths (p<0.001). Death from rupture occurred earlier in patients given thrombolytic therapy, with a clustering of events within 24 h of drug administration. Despite the early risk, death rates were comparatively low in thrombolytic-treated patients on each of the first 30 days. By multivariable analysis, thrombolytics, prior myocardial infarction, advancing age, female gender and intravenous beta-blocker use were independently associated with cardiac rupture.

Conclusions: This large registry experience, including over 350,000 patients with myocardial infarction, suggests that thrombolytic therapy accelerates cardiac rupture, typically to within 24 to 48 h of treatment. The possibility that rupture represents an early hemorrhagic complication of thrombolytic therapy should be investigated.

MeSH terms

  • Age Factors
  • Aged
  • Female
  • Heart Rupture, Post-Infarction / mortality*
  • Humans
  • Male
  • Multivariate Analysis
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Registries
  • Sex Factors
  • Shock, Cardiogenic / mortality
  • Thrombolytic Therapy / adverse effects*
  • United States / epidemiology